Related Experiment Video
Updated: Jun 27, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
Pseudomonas fluorescens Pneumonia: A Case Report and Review of the Literature
1Department of Pulmonology, Hatay Mustafa Kemal University, 31060 Hatay, Türkiye.
Abstract:
Pseudomonas fluorescens is a rare, environmental Gram-negative bacterium that has been rarely reported as a cause of respiratory tract infections. This paper presents a case of a 72-year-old male who developed community-acquired pneumonia due to P. fluorescens. The diagnosis was made by sputum culture and he responded to meropenem treatment. A literature search revealed three previously reported cases of P. fluorescens pneumonia. These cases primarily affected elderly male patients. All reported patients demonstrated positive clinical outcomes following appropriate antimicrobial therapy. This case highlights that although P. fluorescens is often considered a colonizer, it may act as a potential pathogen in selected clinical settings.
Insights
Pseudomonas fluorescens, a rare bacterium, can cause community-acquired pneumonia, particularly in elderly males. Prompt diagnosis and meropenem treatment led to a positive outcome in this case.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonology
Background:
- Pseudomonas fluorescens is an environmental Gram-negative bacterium.
- It is rarely implicated in respiratory tract infections.
- This organism is often considered a colonizer rather than a pathogen.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology

